Unknown

Dataset Information

0

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.


ABSTRACT: BACKGROUND:Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb). The mechanism underlying the resistance to proteasome inhibitors (PIs) for this subset of patients is unknown. METHODS:IC50 of Bzb and carfilzomib (CFZ) in human myeloma cell lines (HMCLs) were established by MTT assay. Gene Expression profile (GEP) analysis was used to determine gene expression in primary myeloma cells. Immunoblotting analysis was performed for MAFb and caspase family proteins. Immunofluorescence staining was used to detect the location of MAFb protein in MM cells. Lentiviral infections were used to knock-down MAFb expression in two lines. Apoptosis detection by flow cytometry and western blot analysis was performed to determine the molecular mechanism MAFb confers resistance to proteasome inhibitors. RESULTS:We found high levels of MAFb protein in cell lines with t(14;20), in one line with t(6;20), in one with Ig? insertion into MAFb locus, and in primary plasma cells from MM patients with t(14;20). High MAFb protein levels correlated with higher IC50s of PIs in MM cells. Inhibition of GSK3? activity or treatment with Bzb or CFZ prevented MAFb protein degradation without affecting the corresponding mRNA level indicating a role for GSK3 and proteasome inhibitors in regulation of MAFb stability. Silencing MAFb restored sensitivity to Bzb and CFZ, and enhanced PIs-induced apoptosis and activation of caspase-3, -?8, -?9, PARP and lamin A/C suggesting that high expression of MAFb protein leads to insensitivity to proteasome inhibitors. CONCLUSION:These results highlight the role of post-translational modification of MAFb in maintaining its protein level, and identify a mechanism by which proteasome inhibitors induced stabilization of MAFb confers resistance to proteasome inhibitors, and provide a rationale for the development of targeted therapeutic strategies for this subset of patients.

SUBMITTER: Qiang YW 

PROVIDER: S-EPMC6035431 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.

Qiang Ya-Wei YW   Ye Shiqiao S   Huang Yuhua Y   Chen Yu Y   Van Rhee Frits F   Epstein Joshua J   Walker Brian A BA   Morgan Gareth J GJ   Davies Faith E FE  

BMC cancer 20180706 1


<h4>Background</h4>Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb). The mechanism underlying the resistance to proteasome inhibitors (PIs) for this subset of patients is unknown.<h4>Methods</h4>IC50 of Bzb and carfilzomib (CFZ) in human myeloma cell lines (HMCLs) were established by MTT assay. Gene Expression profile (GEP) analysis was used to determine gene expression in primary myeloma cells. I  ...[more]

Similar Datasets

| S-EPMC7736847 | biostudies-literature
2024-09-15 | GSE184310 | GEO
| S-EPMC7072336 | biostudies-literature
2020-04-15 | GSE148659 | GEO
| S-EPMC7189287 | biostudies-literature
| S-EPMC5520403 | biostudies-literature
| S-EPMC4602331 | biostudies-literature
| S-EPMC4653030 | biostudies-literature
| S-EPMC4163602 | biostudies-literature
| S-EPMC4508135 | biostudies-literature